Ross Fubini, a director and 10% owner of Ginkgo Bioworks Holdings, Inc., filed an Initial Statement of Beneficial Ownership of Securities with the SEC on June 13, 2024. The Form 3 filing, which is a requirement under Section 16(a) of the Securities Exchange Act of 1934, indicates that Fubini does not beneficially own any non-derivative or derivative securities of the company. The form was filed individually by Fubini and was signed by attorney-in-fact Karen Tepichin on June 14, 2024. This filing is part of the standard regulatory requirements for individuals in Fubini's position and provides transparency into the ownership stakes of company insiders.

Ross Fubini, a director and 10% owner of Ginkgo Bioworks Holdings, Inc., filed an Initial Statement of Beneficial Ownership of Securities with the SEC on June 13, 2024. The Form 3 filing, which is a requirement under Section 16(a) of the Securities Exchange Act of 1934, indicates that Fubini does not beneficially own any non-derivative or derivative securities of the company. The form was filed individually by Fubini and was signed by attorney-in-fact Karen Tepichin on June 14, 2024. This filing is part of the standard regulatory requirements for individuals in Fubini's position and provides transparency into the ownership stakes of company insiders.